Information  X 
Enter a valid email address

Mereo BioPharma Grp (MPH)

  Print   

Monday 28 September, 2020

Mereo BioPharma Grp

Result of General Meeting

RNS Number : 3372A
Mereo BioPharma Group plc
28 September 2020
 

Mereo BioPharma Group plc

 

("Mereo" or the "Company" or the "Group")

 

Result of General Meeting

 

London and Redwood City, Calif., September 28, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces that all five resolutions (the "Resolutions") proposed at the Company's General Meeting ("General Meeting"), held earlier today, were duly passed.  The Board is pleased that all the resolutions received strong support from shareholders.  Full details of the resolutions can be viewed in the Notice of General Meeting on the Company's website at www.mereobiopharma.com

 

The results of the proxy voting in advance of the General Meeting are shown below. On the record date there were 338,713,962 ordinary shares of £0.003 each in issue, each carrying one vote per share.  

 

Resolution

Votes For

Votes at Chairman's Discretion

 

Votes Against

Votes Withheld 

Total Votes Cast 

Result

1

129,413,324

0

9,258,138

17,565

138,689,027

Passed

2

138,317,100

0

178,850

193,077

138,689,027

Passed

3

138,558,837

0

92,945

37,245

138,689,027

Passed

4

125,187,297

0

13,290,680

211,050

138,689,027

Passed

5

124,695,799

0

13,216,200

777,028

138,689,027

Passed

 

 

 

 

 

 

 

 

 

About Mereo BioPharma

 

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.

 

 

Mereo BioPharma Contacts:

 

Mereo

+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer

 

 

 

N+1 Singer (Nominated Adviser and Broker to Mereo )

+44 (0)20 7496 3081

Phil Davies

 

Will Goode

 

 

 

Burns McClellan (US Investor Relations Adviser to Mereo)

+01 212 213 0006

Lisa Burns

 

Steve Klass

 

 

 

FTI Consulting (UK Public Relations Adviser to Mereo )

 +44 (0)20 3727 1000

Simon Conway

 

Ciara Martin

 

 

 

Investors

[email protected]

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMFLFLSAAITFII

a d v e r t i s e m e n t